Results 131 to 140 of about 21,287 (236)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and is characterized by progressive cyst formation in both kidneys and renal function loss. It is the fourth most common cause of end-stage renal disease for which renal replacement therapy has to be started.
openaire +1 more source
Subgroup Analysis of ADPKD with and without radiologic bronchiectasis.
Subgroup Analysis of ADPKD with and without radiologic bronchiectasis.
Ladan Zand (583025) +6 more
core +1 more source
This study investigated the relationship between renalase and diurnal blood pressure (BP) rhythm, left ventricular mass index (LVMI) and carotid intima-media thickness (IMT) in autosomal dominant polycstic kidney disease (ADPKD) patients.
Veysel Erol +9 more
doaj +1 more source
Summary of the pathogenic mutations in Japanese patients with ADPKD.
Summary of the pathogenic mutations in Japanese patients with ADPKD.
Kimiyoshi Sudo (3343949) +15 more
core +1 more source
Frailty Among Patients With ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is a major inherited cause of end-stage kidney disease (ESKD), associated with various systemic complications. Frailty, a degenerative condition linked to adverse health outcomes, may be influenced by ADPKD and its complications; however, data on this association is limited.
Wang, Jui +6 more
openaire +2 more sources
Rationale & Objective: Using OVERTURE (NCT01430494) study data on patient-perceived health, health care utilization, and productivity in autosomal dominant polycystic kidney disease (ADPKD), this research was conducted to characterize the burden of ...
Dorothee Oberdhan +3 more
doaj +1 more source
Renal denervation in ADPKD: an exceptional case
Sympathetic overactivity plays a crucial role in the genesis and aggravation of arterial hypertension in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Marchetiello Cristina +6 more
core
End Point Selection in ADPKD Clinical Trials
Autosomal dominant polycystic kidney disease (ADPKD) is the leading hereditary cause of kidney failure. Challenges have arisen in developing consensus-based clinical trial end points endorsed by the wider ADPKD research community and regulators.
Kitty St Pierre +7 more
doaj +1 more source
Impacts of Metabolic and Mitochondrial Reprogramming on ADPKD Drug Targets and Repurposing
Autosomal dominant polycystic kidney disease (ADPKD) is a complex disorder characterized by the progressive development of renal cysts. Disease progression is linked to ADPKD-driven metabolic and mitochondrial reprogramming that exacerbates ADPKD ...
Phillip H. Chumley +6 more
core +1 more source
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment.
ADPKD is characterized by progressive cyst formation and enlargement leading to kidney failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity.
Chhetri, Parth +3 more
core +1 more source

